MEDEA Biopharma

🌟 MEDEA Biopharma was part of #Curious2024 Future Insight Conference! Organized by Future Insight e.V. and launched by Ulrich Betz from Merck Group, the event focused on breakthrough science topics various areas. 🌍 With 1600 on-site and over 3700 total attendees from 40+ countries, 130 speakers including Ugur Sahin from BioNTech SE and 7 Nobel laureates, the conference offered deep insights about scientific achievements and challenges, among others the antimicrobial resistance, bacteriophages and their potential. Big thanks to the Ministerium für Wirtschaft, Verkehr, Landwirtschaft und Weinbau Rheinland-Pfalz for inviting MEDEA Biopharma! #Bacteriophages #FutureScience #Breakthroughs #Sustainability

Excited to share highlights from our recent days in Lausanne, as participants of the MassChallenge Switzerland 2024 cohort, where MEDEA Biopharma won the Bühler Group's competition! MEDEA Biopharma was selected among the elite 8% of startups chosen from a worldwide applicant pool. This opportunity enabled us to explore collaborations and the opportunities of our next generation sustainable antibacterial substances with corporate partners such as Nestlé, dsm-firmenich, Bühler Group, Südzucker, Omyam, Givaudan and many more. A big thank you to the whole the MassChallenge Switzerland team! Matthew Lashmar, Nicolas Meneses, Giorgia Scetta, PhD, Marco Iotti, Elodie Waquet, Hendrik Marcel Dik, Augustin Woronoff, and all the contributors. #MassChallenge #Startup #Medea #bacteriophages #sustainability

Hanno Charisius' recent article in Süddeutsche Zeitung highlights the growing importance of bacteriophages in combating antibiotic resistance of bacteria. Sharing such information helps to raise awareness for urgent need of new solutions and large potential of bacteriophages. #AntibioticResistance #Bacteriophages #InnovativeTherapies #HealthcareInnovation #Biotechnology

🚀 Exciting News! MEDEA Biopharma has been selected as finalists in the prestigious MassChallenge Switzerland 2024! This recognition places us among the world’s most innovative and impactful young enterprises. 💡🧬 Being part of this exclusive program offers us new opportunities for growth, mentorship, and global networking. We look forward to leveraging this platform to drive our mission forward. 🌐🤝

🚀 Exciting News! MEDEA Biopharma has been selected as finalists in the prestigious MassChallenge Switzerland 2024! This recognition places us among the world’s most innovative and impactful young enterprises. 💡🧬 Being part of this exclusive program offers us new opportunities for growth, mentorship, and global networking. We look forward to leveraging this platform to drive our mission forward. 🌐🤝

🚀 MEDEA Biopharma is attending 𝐏𝐞𝐭𝐜𝐚𝐫𝐞 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐄𝐮𝐫𝐨𝐩𝐞 2024, 4-5 June in Berlin! 🐾 🧬 Looking forward to meeting with industry stakeholders from across Europe to dig into the latest trends and innovations driving the petcare industry forward! 🚀 Join us in Berlin: https://hubs.ly/Q027bQRG0 #PCI2024 #petcareinnovation #petcare #bacteriophages #phages #biotech

🚨 The World Health Organization warns of rising antibiotic resistance, posing a significant threat to global health and updates list of drug-resistant bacteria most threatening to human health❗ With 𝐚𝐧𝐭𝐢𝐦𝐢𝐜𝐫𝐨𝐛𝐢𝐚𝐥 𝐫𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐜𝐞 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐧𝐠 𝐭𝐨 𝐚𝐫𝐨𝐮𝐧𝐝 𝐟𝐢𝐯𝐞 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐝𝐞𝐚𝐭𝐡𝐬 𝐚𝐧𝐧𝐮𝐚𝐥𝐥𝐲, it's critical to invest in new treatments. At MEDEA Biopharma, we’re pioneering sustainable 𝐩𝐡𝐚𝐠𝐞-𝐛𝐚𝐬𝐞𝐝 𝐚𝐧𝐭𝐢𝐛𝐚𝐜𝐭𝐞𝐫𝐢𝐚𝐥𝐬 to tackle this crisis and to target resistant bacteria. Join us in the fight against antimicrobial resistance and help secure a healthier future. 🌍🔬 #Healthcare #Biotech #Innovation #AMR #PhageTherapy #Medea

🔬 Exciting news and great progress for phage therapy! 🌐 The 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐩𝐨𝐞𝐢𝐚 𝐂𝐨𝐦𝐦𝐢𝐬𝐬𝐢𝐨𝐧 (𝐄𝐏𝐂) has adopted the first 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐩𝐨𝐞𝐢𝐚 𝐭𝐞𝐱𝐭 on phage therapy medicinal products. This significant advancement establishes a standardized framework of requirements for the production and control of phage therapy products, a crucial step forward for the field! At MEDEA Biopharma, the new chapter in the 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐩𝐨𝐞𝐢𝐚 aligns with our commitment to developing safe and effective antibacterial solutions as antimicrobial resistance continues to be a significant global health threat. #PhageTherapy #Biotech #Innovation #PublicHealth #EDQM

📰 Exciting article on Forbes! 💡 Rob Kniaz, Managing Partner at Hoxton Ventures, highlights the immense potential of phages to combat antibiotic resistance and to revolutionize both animal and human health industries. 🧬 At MEDEA Biopharma, we're developing cutting-edge sustainable phage-based antibacterial solutions. 🚀 #BiotechInnovation #PhageTherapy #HealthcareRevolution

MEDEA Biopharma was present at the 𝐀𝐍𝐈𝐌𝐀𝐋 𝐇𝐄𝐀𝐋𝐓𝐇, 𝐍𝐔𝐓𝐑𝐈𝐓𝐈𝐎𝐍 𝐀𝐍𝐃 ����𝐄𝐂𝐇𝐍𝐎𝐋𝐎𝐆𝐘 𝐈𝐍𝐍𝐎𝐕𝐀𝐓𝐈𝐎𝐍 𝐄𝐔𝐑𝐎𝐏𝐄 2024 in 𝐋𝐨𝐧𝐝𝐨𝐧 this week! 🌍 The event provides a great opportunity to dive deep into the latest trends and innovations shaping the future of animal health and nutrition, and to showcase our approach 𝐚𝐧𝐭𝐢𝐛𝐚𝐜𝐭𝐞𝐫𝐢𝐚𝐥 solutions 𝐛𝐚𝐬𝐞𝐝 𝐨𝐧 𝐛𝐚𝐜𝐭𝐞𝐫𝐢𝐨𝐩𝐡𝐚𝐠𝐞𝐬. 🐄 🔬 🧪 #AnimalHealth #BiotechInnovation #Bacteriophages #AHNTI2024